Our cells need a constant supply of oxygen to power their diverse molecular processes. This oxygen is delivered by the blood, so nearly all of our cells are within a tenth of a millimeter from a blood capillary. Tumor cells are no exception. If a collection of cancerous cells grows much larger than a millimeter, it will starve itself of oxygen and energy unless new blood vessels are built to provide a supply. For this reason, many cancer cells co-opt the normal processes of angiogenesis, the development of blood vessels, in order to build their own blood supply.
Vascular endothelial growth factor, or VEGF (shown in Fig. 1 ), is the key signal used by oxygen-hungry cells to promote growth of blood vessels. It binds to specialized receptors on the surfaces of endothelial cells (shown in Fig. 2 ) and directs them to build new vessels. After receiving this message, the cells build specialized proteases to break through the basal lamina, and migrate into the oxygen-starved region.
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LEARNING OBJECTIVE
After completing this course, the reader will be able to:
Gain a basic understanding of VEGF and its role in angiogenesis.
Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME Tumor cells use these same processes to create their own oxygen supply. Through mutation, they gain the ability to create abnormally large amounts of VEGF or to block the action of inhibitors of angiogenesis. This is often termed the "angiogenic switch," marking a key transition as cancer cells gain the ability to direct their own blood supply. Given a ready blood supply, the tumor can grow much larger. The switch also enhances the ability of the tumor to metastasize, since a custom-made blood supply can be constructed wherever new tumors begin to grow.
As you can imagine, this is an attractive process for the design of cancer therapy. By selectively inhibiting the growth of new blood vessels, we can starve tumor cells. Effective methods have been developed to do just this, using drugs or antibodies to block the formation of VEGF or the binding of VEGF to its receptors. Researchers have found, however, that these methods are effective for stopping the growth of a tumor, but generally not for reducing the size of an existing tumor. They are powerful tools, however, when used in combination with agents that attack other key points in the tumor cell. 
